CareDx, Inc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Walter Hanna Jr.
- Full Time Employees
- 644
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1 Tower Place South San Francisco CA United States of America 94080
- IPO Date
- Jul 17, 2014
- CIK
- 0001217234
- Website
- caredx.com
- Similar Companies
- Business
- CareDx, Inc. CareDx, Inc. (Nasdaq: CDNA) operates as a leading precision medicine company focused on the discovery, development, and commercialization of diagnostic solutions, testing services, products, and digital healthcare tools for transplant patients and caregivers along the pre- and post-transplant journey. The company offers core products and services including AlloSure Kidney, AlloSure Heart, AlloSure Lung, and AlloMap Heart gene expression profiling tests, which utilize donor-derived cell-free DNA (dd-cfDNA) for noninvasive surveillance to detect organ injury and rejection in kidney, heart, and lung transplant recipients; AlloSeq and QTYPE for superior HLA typing with hybrid capture technology; HeartCare, combining AlloMap Heart and AlloSure Heart; digital solutions such as the AlloCare mobile app for patient medication management, health tracking, and care coordination, and transplant administration software like Ottr acquired via TransChart in 2021; transplant lab products for matching; and pharma services to accelerate biopharma clinical development. Founded in 1998 and headquartered in Brisbane, California, with principal operations in South San Francisco, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden, CareDx primarily generates revenue from the United States while serving over 150 U.S. transplant centers and more than 30,000 patients. Recent developments include the launch of AlloSure Plus (formerly AlloView), an AI-driven diagnostic platform integrating dd-cfDNA with clinical methods for improved rejection prediction; new IVD products and IVDR certification for AlloSeq Tx and QTYPE announced at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting; the launch of HistoMap Kidney, a tissue-based gene expression assay to characterize rejection phenotypes, planned for early 2026; partnerships such as with Leidos to transform the Organ Procurement and Transplantation Network, TC BioPharm for AML therapy trials using AlloCell testing, and agreements with Illumina and Cibiltech; installation of the EPIC environment and customer pilots; and strong Q3 2025 financial results with 21% revenue growth, 30% increase in patient and digital solutions revenue, and improved profitability.
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baron Discovery Fund Q1 2026: Who Moved The Needle
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx to Participate in Upcoming Investor Conferences
CareDx Announces Dismissal of 2021 Qui Tam Suit
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx Announces First Quarter 2026 Financial Results
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual Meeting
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
CareDx Sharpens Focus On Core Testing Services
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results
CareDx to Report First Quarter 2026 Financial Results on April 28, 2026
Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA